

Electronic Supporting Information (ESI)

Zinc Hydride Catalyzed Hydroboration of Esters

A Ganesh Patro,[‡] Rajata Kumar Sahoo,[‡] and Sharanappa Nembenna*

School of Chemical Sciences, National Institute of Science Education and Research (NISER), Homi Bhabha National Institute (HBNI), Bhubaneswar, 752 050, India

*Corresponding author: snembenna@niser.ac.in

Tel: +91-674-2494174


[‡]Both authors contributed equally

Contents

- Analytical Data for Hydroboration of Esters and Other Carbonyls
- NMR Spectra (¹H, ¹³C{¹H} and ¹¹B NMR) of Stoichiometric Experiments
- ¹H, ¹³C{¹H} and ¹¹B NMR Spectra of Hydroboration of Esters and Other Carbonyl Compounds
- X-ray Crystallographic Data of **Int A1'**
- References

Analytical data for Hydroboration of Esters and other Carbonyls:


2-(benzyloxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2a)¹: White solid, NMR Conv.:



>99%; ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.03 (m, 5H), 4.83 (s, 2H), 1.15 (s, 12H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 139.2, 128.3, 127.4, 126.7, 82.9, 66.7, 24.6.

4,4,5,5-tetramethyl-2-((4-methoxybenzyl)oxy)-1,3,2-dioxaborolane (2b)¹, 2-methoxy-


4,4,5,5-tetramethyl-1,3,2-dioxaborolane¹: White solid, NMR Conv.: >99%; ¹H NMR (400



MHz, CDCl₃) δ 7.31 – 7.29 (d, *J* = 8.7 Hz, 2H), 6.89 – 6.87 (d, *J* = 8.7 Hz, 2H), 4.87 (s, 2H), 3.82 (s, 3H), 3.62 (s, 3H), 1.29 (s, 12H),

1.28 (s, 12H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 159.0, 131.4, 128.5, 113.6, 82.8, 82.7, 66.4, 55.2, 52.6, 24.8, 24.6.


4,4,5,5-tetramethyl-2-((4-nitrobenzyl)oxy)-1,3,2-dioxaborolane (2c)¹, 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane¹: White solid, NMR Conv.: >99%; ¹H NMR (400 MHz,



CDCl₃) δ 8.22 – 8.20 (d, *J* = 8.7 Hz, 2H), 7.53 – 7.51 (d, *J* = 8.9 Hz, 2H), 5.04 (s, 3H), 3.61 (s, 2H), 1.29 (s, 12H), 1.27 (s, 12H). ¹³C{¹H} NMR

(101 MHz, CDCl₃) δ 146.6, 126.8, 123.5, 83.3, 82.7, 65.5, 52.6, 24.6, 24.5.


4,4,5,5-tetramethyl-2-((4-(trifluoromethyl)benzyl)oxy)-1,3,2-dioxaborolane (2d)¹, 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane¹: White solid, NMR Conv.: >99%; ¹H



NMR (400 MHz, CDCl₃): δ = 7.60 – 7.59 (d, *J* = 8.0 Hz, 2H), 7.47 – 7.45 (d, *J* = 8.0 Hz, 2H), 4.99 (s, 2H), 3.61 (s, 3H), 1.27 (s, 12H),

1.26 (s, 12H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ = 143.2, 129.9, 129.3, 126.5, 125.2, 125.1, 122.8, 83.1, 82.7, 65.8, 52.5, 24.5. ¹¹B NMR (128 MHz, CDCl₃): δ = 22.29 ppm.


4,4,5,5-tetramethyl-N-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(4-(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)benzyl)-1,3,2-dioxaborolan-2-amine



(2e)², 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane¹: White solid, NMR Conv.: >99%; ¹H NMR (400 MHz, CDCl₃) δ 7.28 – 7.26 (d, *J* = 8.5 Hz, 2H), 7.24 – 7.22 (d, *J* = 8.4

Hz, 2H), 4.88 (s, 2H), 4.22 (s, 2H), 3.61 (s, 3H), 1.28 (s, 12H), 1.26 (s, 12H), 1.20 (s, 24H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 142.2, 136.9, 127.3, 126.3, 83.2, 82.8, 82.2, 66.6, 52.5, 46.9, 24.8, 24.6, 24.4


2-((4-chlorobenzyl)oxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2f)³, 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane¹: White solid, NMR Conv.: >99%; ¹H NMR (400 MHz,



CDCl₃) δ 7.32 – 7.28 (m, 4H), 4.90 (s, 2H), 3.62 (s, 3H), 1.28 (s, 12H), 1.27 (s, 12H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 137.7,

133.1, 128.4, 128.0, 83.2, 83.0, 65.9, 52.6, 24.8, 24.6.

1,4-bis(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)benzene (2g)¹, 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane¹: White solid, NMR Conv.: >99%; ¹H




NMR (400 MHz, CDCl₃) δ 7.32 (s, 4H), 4.92 (s, 3H), 3.61 (s, 3H), 1.28 (s, 12H), 1.27 (s, 12H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 138.4, 126.7,

83.2, 82.8, 66.4, 52.5, 24.8, 24.5.

4,4,5,5-tetramethyl-2-((4-(1-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-

yl)oxy)ethyl)benzyl)oxy)-1,3,2-dioxaborolane (2h)⁴, 2-methoxy-4,4,5,5-tetramethyl-1,3,2-



dioxaborolane¹: White solid, NMR Conv.:>99%; ¹H NMR (400 MHz, CDCl₃) δ 7.33 –


7.31 (d, *J* = 5.9 Hz, 4H), 5.25 – 5.23 (m, 1H), 4.91 (s, 2H), 3.61 (s, 3H), 1.49 – 1.48 (d, *J* = 6.5

Hz, 3H), 1.28 (s, 12H), 1.27 (s, 12H), 1.25 – 1.22 (d, *J* = 5.9 Hz, 12H). ¹³C{¹H} NMR (101

MHz, CDCl₃) δ 143.8, 138.1, 126.6, 125.2, 83.2, 82.8, 82.6, 72.3, 66.5, 52.5, 25.3, 24.8, 24.5, 24.5.

2-(benzyloxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2a)¹, 4,4,5,5-tetramethyl-2-

phenoxy-1,3,2-dioxaborolane (2i)¹: White solid, NMR Conv.:>99%; ¹H NMR (400 MHz,



CDCl₃) δ 7.40 – 7.36 (m, 4H), 7.33 – 7.26 (m,


3H), 7.19 – 7.04 (m, 3H), 4.96 (s, 2H), 1.35

(s, 12H), 1.30 (s, 12H). ¹³C{¹H} NMR (101

MHz, CDCl₃) δ 153.4, 139.2, 129.3, 128.2, 127.3, 126.7, 123.0, 119.5, 83.5, 82.9, 66.6, 24.6, 24.6.

2-(benzyloxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2a)¹, 2-(benzyloxy)-4,4,5,5-

tetramethyl-2-(*p*-tolyl)oxy)-1,3,2-dioxaborolane (2j)¹: White solid, NMR Conv.:>99%; ¹H




NMR (400 MHz, CDCl₃) δ 7.25 – 7.24 (d, *J* = 6.5

Hz, 5H), 6.98 – 6.96 (d, *J* = 8.0 Hz, 2H), 6.89 –

6.87 (d, *J* = 7.9 Hz, 2H), 4.84 (s, 2H), 2.19 (s,

3H), 1.22 (s, 12H), 1.17 (s, 24H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 151.2, 139.2, 132.3, 129.7, 128.2, 127.3, 126.7, 119.2, 83.4, 82.9, 66.6, 24.8, 24.6, 20.6.


2-(benzyloxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2a)¹, 4,4,5,5-tetramethyl-2-(4-nitrophenoxy)-1,3,2-dioxaborolane (2k)¹: White solid, NMR Conv.: >99%; ¹H NMR (700



MHz, CDCl₃) δ 8.21 – 8.20 (d, *J* = 9.2 Hz, 2H), 7.38 – 7.34 (d, *J* = 25.1 Hz, 4H), 7.30 – 7.25 (d, *J* = 32.6 Hz, 3H), 4.95 (s, 2H), 1.37

(s, 12H), 1.29 (s, 12H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 158.6, 139.2, 128.2, 127.3, 126.7, 125.4, 120.0, 84.2, 82.9, 66.6, 24.8, 24.6.


2-(benzyloxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2a)¹, 4,4,5,5-tetramethyl-2-phenethoxy-1,3,2-dioxaborolane (2l)¹: White solid, NMR Conv.: >99%; ¹H NMR (400 MHz,



CDCl₃): δ = 7.42 – 7.38 (t, *J* = 8.0 Hz, 3H), 7.36 – 7.25 (m, 7H), 5.00 (s, 2H), 4.13 (t, *J* = 8.0 Hz, 2H), 2.94 (t, *J* = 8.0 Hz, 2H), 1.32

(s, 12H), 1.25 (s, 12H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ 139.3, 138.5, 129.1, 128.3, 127.4, 126.7, 126.2, 82.9, 82.6, 66.7, 65.7, 38.1, 24.6, 24.5. ¹¹B NMR (128 MHz, CDCl₃): δ 22.34 ppm.


4,4,5,5-tetramethyl-2-(prop-2-yn-1-yloxy)-1,3,2-dioxaborolane (2m)⁵, 2-ethoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2o)¹: White solid, NMR Conv.: >99%; ¹H NMR (400



MHz, CDCl₃): δ = 4.20 – 4.12 (m, 2H), 3.84 (q, *J* = 8.0 Hz, 2H), 2.91 (s, 1H), 1.19 (s, 12H), 1.17 (s, 12H), 1.14 (t, *J* = 8.0 Hz, 3H). ¹³C{¹H} NMR

(101 MHz, CDCl₃): δ 85.1, 83.0, 82.5, 74.6, 62.2, 60.5, 24.5, 24.4, 17.1.

(E)-2-((3-methoxyallyl)oxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2n), 2-methoxy-




4,4,5,5-tetramethyl-1,3,2-dioxaborolane¹:

White solid, NMR Conv: >99%; ¹H NMR (400 MHz, CDCl₃) δ 7.60 – 7.57 (d, *J* = 12.7 Hz, 1H), 5.17 – 5.14 (d, *J* = 12.6 Hz, 1H), 3.66 (s, 2H),


3.65 (s, 3H), 3.56 (s, 3H), 1.21 (s, 24H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 163.1, 95.5, 82.6, 57.1, 52.4, 50.9, 24.5. ^{11}B NMR (128 MHz, CDCl_3): δ 22.17 ppm.

2-ethoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2o)⁶: White solid, NMR Conv.: >99%;




^1H NMR (400 MHz, CDCl_3) δ 3.93 – 3.88 (m, 2H), 1.26 (s, 12H), 1.25 – 1.21 (d, J = 7.0 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 82.5, 60.6, 24.5, 17.1.

4,4,5,5-tetramethyl-2-propoxy-1,3,2-dioxaborolane (2p)¹: White solid, NMR Conv.: >99%;



^1H NMR (400 MHz, CDCl_3) δ 3.72 (t, J = 6.5 Hz, 2H), 1.54 – 1.49 (dd, J = 14.1, 7.0 Hz, 2H), 1.18 (s, 12H), 0.84 (t, J = 7.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 82.5, 66.5, 24.6, 24.5, 10.0.


2,2'-(butane-1,4-diylbis(oxy))bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (2q)⁷: White



solid, NMR Conv.: >99%; ^1H NMR (400 MHz, CDCl_3): δ = 4.29 – 4.24 (m, 1H), 3.85 (t, J = 8.0 Hz, 2H), 1.35 – 1.31 (m, 2H), 1.22 (s, 12H), 1.20 (s, 12H), 1.17 – 1.16 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$

NMR (101 MHz, CDCl_3): δ 82.5, 82.4, 67.8, 61.6, 39.6, 24.5, 24.3, 22.5. ^{11}B NMR (128 MHz, CDCl_3): δ 21.91 ppm.


4,4,5,5-tetramethyl-2-(2-phenyl-5-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-



yl)oxy)pentyl)-1,3,2-dioxaborolane (2r)⁸: White solid, NMR Conv.: >99%; ^1H NMR (400 MHz, CDCl_3): δ = 7.36 – 7.34 (d, J = 8.0 Hz, 2H), 7.33 – 7.27 (d, J = 8.0 Hz, 2H), 7.26 – 7.22 (m, 1H), 5.08 (t, J =


6.4 Hz, 1H), 3.85 (t, J = 6.4 Hz, 2H), 1.88 – 1.78 (m, 2H), 1.70 – 1.56 (m, 2H), 1.29 (s, 12H), 1.25 (s, 12H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3): δ = 143.3, 128.0, 127.1, 125.8, 82.7, 82.6, 76.1, 64.6, 35.1, 27.4, 24.8, 24.5.

2,2'-(propane-1,2-diylbis(oxy))bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (2s)¹: White



solid, NMR Conv.: >99%; ¹H NMR (400 MHz, CDCl₃) δ 5.17 – 5.15 (m, 1H), 3.92 – 3.72 (d, *J* = 8.7 Hz, 2H), 1.28 (s, 24H), 1.19 – 1.18 (d, *J* = 5.7 Hz, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ = 92.6, 83.2, 83.1, 71.6, 24.8, 24.5, 15.2.


1,5-bis((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)pentane (2t)¹: White solid, NMR



Conv.: >99%; ¹H NMR (400 MHz, CDCl₃): δ = 3.85 – 3.82 (m, 4H), 1.63 – 1.57 (m, 4H), 1.47 – 1.34 (m, 2H), 1.25 (s, 24H). ¹³C{¹H} NMR (101 MHz, CDCl₃): δ =

82.5, 64.7, 31.0, 24.5, 21.6.


2,2'-(decane-1,4-diylbis(oxy))bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane) (2u)¹: White



solid, NMR Conv.: >99%; ¹H NMR (700 MHz, CDCl₃) δ 5.76- 5.63 (d, *J* = 87.0 Hz, 1H), 4.11 – 3.90 (d, *J* = 146.4 Hz, 2H), 2.14 – 1.82 (m, 4H), 1.76 – 1.62 (m, 2H), 1.60 - 1.45 (m, 2H), 1.43 - 1.35 (m, 2H), 1.30 – 1.27 (m, 4H), 1.27

– 1.26 (m, 12H), 1.26 – 1.24 (m, 12H), 0.87 (t, *J* = 74.0 Hz 3H) . ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 99.0, 82.7, 81.5, 79.0, 37.3, 34.7, 31.8, 29.2, 28.6, 26.1, 24.8, 24.5, 22.5, 14.0.

4,4,5,5-tetramethyl-2-(4-nitrophenoxy)-1,3,2-dioxaborolane (4a)¹, 2-methoxy-4,4,5,5-




tetramethyl-1,3,2-dioxaborolane¹:

White solid, NMR Conv: >99%; ¹H NMR (400 MHz, CDCl₃) δ 8.10 – 8.08 (d, *J* =

8.7 Hz, 2H), 7.17 – 7.14 (d, *J* = 8.9 Hz, 2H), 3.51 (s, 3H), 1.26 (s, 12H), 1.18 (s, 12H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 158.6, 143.3, 125.4, 120.0, 84.2, 83.0, 52.5, 24.5, 24.5.


2-(4-bromophenoxy)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (6a)¹, 2,2'-oxybis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane)¹: White solid, NMR Conv: >99%; ¹H NMR (400 MHz,



CDCl₃) δ 7.38 -7.36 (d, *J* = 7.4 Hz, 2H), 7.15 – 7.13 (d, *J* = 7.6 Hz, 2H), 4.79 (s, 2H), 1.18 (s, 36H). ¹³C{¹H} NMR (101

MHz, CDCl₃) δ 138.2, 131.3, 128.4, 121.1, 83.0, 81.9, 65.9, 24.5, 22.6.

1,2-bis(((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxy)methyl)benzene (8a)⁹, 2,2'-oxybis(4,4,5,5-tetramethyl-1,3,2-dioxaborolane)¹:



White solid, NMR Conv: >99%; ¹H NMR (400 MHz, CDCl₃) δ 7.38 – 7.35 (d, *J* = 8.8 Hz, 2H), 7.21 – 7.17 (d, *J* = 8.8 Hz, 2H), 4.91 (s, 4H), 1.19 (s, 24H), 1.18

(s, 24H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 147.3, 137.2, 130.6, 120.9, 83.1, 82.9, 34.1, 24.6, 24.5.

NMR Spectra (^1H , $^{13}\text{C}\{^1\text{H}\}$ and ^{11}B NMR) of Stoichiometric Experiments




Figure S1: ^1H NMR of compound $[\text{LZnOCH}_2\text{C}_6\text{H}_5]_2$ (**Int A1**) (400 MHz, C_6D_6 , 25 $^\circ\text{C}$)




Figure S2: $^{13}\text{C}\{^1\text{H}\}$ NMR of compound $[\text{LZnOCH}_2\text{C}_6\text{H}_5]_2$ (**Int A1**) (100 MHz, C_6D_6 , 25 $^\circ\text{C}$)

Synthesis of [LZnH]₂ and 2a {NMR-Scale}: The addition of HBpin (6 μ L, 0.042 mmol) to a J. Young valve NMR tube containing a solution of compounds **Int A1** (0.021 mmol) in C₆D₆ resulted in the formation of compounds **I** and **2a** at rt after 6h as observed by ¹H NMR spectroscopy. NMR Conversion >99%.




Figure S3: ¹H NMR of compounds **I** and **2a** (400 MHz, C₆D₆, 25 °C)




Figure S4: ¹³C{¹H} NMR of compounds **I** and **2a** (100 MHz, C₆D₆, 25 °C)




Figure S5: ¹H NMR monitoring: the stoichiometric reaction of benzoyl benzoate with HBpin and compound **I**.




Figure S6: Zoom ^1H NMR monitoring: the stoichiometric reaction of benzoyl benzoate with HBpin and compound **I**.




Figure S7: ^1H NMR of compounds **Int A1** and **Int A1'** (400 MHz, C_6D_6 , 25 °C)




Figure S8: $^{13}\text{C}\{^1\text{H}\}$ NMR of compounds **Int A1** and **Int A1'** (100 MHz, C_6D_6 , 25 °C)

Synthesis of $[\text{LZnH}]_2$, **2a and **2j** {NMR-Scale}:** The addition of HBpin (6 μL , 0.042 mmol) to a J. Young valve NMR tube containing a solution of compounds **Int A1** and **Int A1'** (0.021 mmol) in C_6D_6 resulted in the formation of compounds **I**, **2a**, and **2j** at rt after 6h as observed by ^1H NMR spectroscopy. NMR Conversion >99%.




Figure S9: ¹H NMR of compounds **I**, **2a** and **2j** (400 MHz, C₆D₆, 25 °C)




Figure S10: ¹³C{¹H} NMR of compounds **I**, **2a** and **2j** (100 MHz, C₆D₆, 25 °C)

^1H , $^{13}\text{C}\{^1\text{H}\}$ and ^{11}B NMR Spectra of Hydroboration of Esters and Other Carbonyl Compounds




Figure S11: ^1H NMR spectrum of compound **1a**+HBpin (400 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S12: $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **1a**+HBpin (100 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S13: ^{11}B NMR spectrum of compound **1a**+HBpin (176 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S14: ^1H NMR spectrum of compound **2a** (400 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S15: ¹³C{¹H} NMR spectrum of compound **2a** (101 MHz, CDCl₃, 25 °C)




Figure S16: ¹H NMR spectrum of compounds **2b** and MeOBpin (400 MHz, CDCl₃, 25 °C)




Figure S17: ¹³C{¹H} NMR spectrum of compounds **2b** and MeOBpin (101 MHz, CDCl₃, 25 °C)




Figure S18: ¹H NMR spectrum of compounds **2c** and MeOBpin (400 MHz, CDCl₃, 25 °C).




Figure S19: ¹³C{¹H} NMR spectrum of compounds **2c** and MeOBpin (101 MHz, CDCl₃, 25 °C)




Figure S20: ¹H NMR spectrum of compounds **2d** and MeOBpin (400 MHz, CDCl₃, 25 °C)




Figure S21: ¹³C{¹H} NMR spectrum of compounds **2d** and MeOBpin (101 MHz, CDCl₃, 25 °C)




Figure S22: ¹¹B NMR spectrum of compounds **2d** and MeOBpin (128 MHz, CDCl₃, 25 °C)




Figure S23: ^1H NMR spectrum of compounds **2e** and MeOBpin (400 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S24: $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compounds **2e** and MeOBpin (101 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S25: ^1H NMR spectrum of compounds **2f** and MeOBpin (400 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S26: $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compounds **2f** and MeOBpin (101 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S27: ¹H NMR spectrum of compounds **2g** and MeOBpin (400 MHz, CDCl₃, 25 °C)




Figure S28: ¹³C{¹H} NMR spectrum of compounds **2g** and MeOBpin (101 MHz, CDCl₃, 25 °C)




Figure S29: ¹H NMR spectrum of compounds **2h** and MeOBpin (400 MHz, CDCl₃, 25 °C)




Figure S30: ¹³C{¹H} NMR spectrum of compounds **2h** and MeOBpin (101 MHz, CDCl₃, 25 °C)




Figure S31: ¹H NMR spectrum of compounds **2a** and **2i** (400 MHz, CDCl₃, 25 °C)




Figure S32: ¹³C{¹H} NMR spectrum of compounds **2a** and **2i** (101 MHz, CDCl₃, 25 °C)




Figure S33: ¹H NMR spectrum of compounds **2a** and **2j** (400 MHz, CDCl₃, 25 °C)




Figure S34: ¹³C{¹H} NMR spectrum of compounds **2a** and **2j** (101 MHz, CDCl₃, 25 °C)




Figure S35: ¹H NMR spectrum of compounds **2a** and **2k** (400 MHz, CDCl₃, 25 °C)




Figure S36: ¹³C{¹H} NMR spectrum of compounds **2a** and **2k** (101 MHz, CDCl₃, 25 °C)




Figure S37: ^1H NMR spectrum of compounds **2a** and **2l** (400 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S38: $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compounds **2a** and **2l** (101 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S39: ^{11}B NMR spectrum of compounds **2a** and **2l** (128 MHz, CDCl_3 , 25 °C)




Figure S40: ^1H NMR spectrum of compounds **2m** and **2o** (400 MHz, CDCl_3 , 25 °C)




Figure S41: $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compounds **2m** and **2o** (101 MHz, CDCl_3 , 25 °C)




Figure S42: ^1H NMR spectrum of compounds **2n** and MeOBpin (400 MHz, CDCl_3 , 25 °C)




Figure S43: $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compounds **2n** and MeOBpin (101 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S44: ^{11}B NMR spectrum of compounds **2n** and MeOBpin (128 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S45: ¹H NMR spectrum of compound **2o** (400 MHz, CDCl₃, 25 °C)




Figure S46: ¹³C{¹H} NMR spectrum of compound **2o** (101 MHz, CDCl₃, 25 °C)




Figure S47: ¹H NMR spectrum of compound **2p** (400 MHz, CDCl₃, 25 °C)




Figure S48: ¹³C{¹H} NMR spectrum of compound **2p** (101 MHz, CDCl₃, 25 °C)




Figure S49: ¹H NMR spectrum of compound **2q** (400 MHz, CDCl₃, 25 °C)




Figure S50: ¹³C{¹H} NMR spectrum of compound **2q** (101 MHz, CDCl₃, 25 °C)




Figure S51: ¹¹B NMR spectrum of compound **2q** (128 MHz, CDCl₃, 25 °C)




Figure S52: ¹H NMR spectrum of compound **2r** (400 MHz, CDCl₃, 25 °C)




Figure S53: $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **2r** (101 MHz, CDCl_3 , 25 °C)




Figure S54: ^1H NMR spectrum of compound **2s** (400 MHz, CDCl_3 , 25 °C)




Figure S55: $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound 2s (101 MHz, CDCl_3 , 25 °C)




Figure S56: ^1H NMR spectrum of compound 2t (400 MHz, CDCl_3 , 25 °C)




Figure S57: $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **2t** (101 MHz, CDCl_3 , 25 °C)




Figure S58: ^1H NMR spectrum of compound **2u** (400 MHz, CDCl_3 , 25 °C)




Figure S59: $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **2u** (101 MHz, CDCl_3 , 25 °C)




Figure S60: ^1H NMR spectrum of compound **2a'** (400 MHz, CDCl_3 , 25 $^\circ\text{C}$)




Figure S61: $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **2a'** (101 MHz, CDCl_3 , 25 °C)




Figure S62: ^1H NMR spectrum of compounds **4a** and MeOBpin (400 MHz, CDCl_3 , 25 °C)




Figure S63: ¹³C{¹H} NMR spectrum of compounds **4a** and MeOBpin (101 MHz, CDCl₃, 25 °C)




Figure S64: ¹H NMR spectrum of compounds **6a** and (Bpin)₂O (400 MHz, CDCl₃, 25 °C)




Figure S65: ¹³C{¹H} NMR spectrum of compounds **6a** and (Bpin)₂O (101 MHz, CDCl₃, 25 °C)




Figure S66: ¹H NMR spectrum of compounds **8a** and (Bpin)₂O (400 MHz, CDCl₃, 25 °C)




Figure S67: $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compounds **8a** and $(\text{Bpin})_2\text{O}$ (101 MHz, CDCl_3 , 25 $^\circ\text{C}$)

X-ray Crystallographic Data of Int A1'

The compound Int A1' single crystals were crystallized from benzene at rt as colorless blocks after 1 d. Compound Int A1' crystal data was collected on a Rigaku Oxford diffractometer at 100 K. The crystal data of compounds **Int A1'** is collected on a Rigaku Oxford diffractometer with graphite-monochromated Cu-K α radiation ($\lambda = 1.54184 \text{ \AA}$) at 100 K. Selected data collection parameters and other crystallographic results are summarized in Table S1. The structure was determined using direct methods employed in *ShelXT*,¹⁰ *OleX*,¹¹ and refinement was carried out using least-square minimization implemented in *ShelXL*.¹² All non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atom positions were fixed geometrically in idealized positions and were refined using a riding model.




Figure 68. Molecular structure of **Int A1'**. The thermal ellipsoids are shown at 50% probability, and all the hydrogen atoms except those bound to nitrogen atoms and ethyl groups have been removed for clarity. Selected bond lengths (Å) and angles (deg), For **Int A1'**: Zn1-Zn1' 3.0844(7), Zn1-N1 1.974(2), Zn1-N2 1.965(2), Zn1-O1 1.972(2), Zn1-O1' 2.040(2); N1-Zn1-N2 94.84(10), N1-Zn1-O1 124.04(10), N2-Zn1-O1 126.95(10), O1-Zn1-O1' 79.49(10), Zn1-O1-Zn1' 100.51(10).

Table S1. Crystallographic Data and Refinement Parameters for Compound **Int A1'**.

Compound	Int A1'
Empirical Formula	C ₉₈ H ₁₂₂ N ₁₀ O ₂ Zn ₂
CCDC	2245811
Molecular mass	1602.79
Temperature (K)	100.00(10)
Wavelength (Å)	1.54184
Size(mm)	0.2×0.18×0.17
Crystal system	monoclinic
Space group	P2 ₁ /n
a (Å)	15.62480(10)
b (Å)	14.65430(10)
c (Å)	19.2404(2)
α (deg) ^o	90
β (deg) ^o	99.8730(10)
γ (deg) ^o	90
Volume (Å ³)	4340.24(6)
Z	2
Calculated density (g/cm ³)	1.226
Absorption coefficient (mm ⁻¹)	1.097
F(000)	1712.0
Theta range for data collection (deg) ^o	6.748 to 151.398
Limiting indices	-18 ≤ h ≤ 19, -17 ≤ k ≤ 18, -24 ≤ l ≤ 17
Reflections collected	38610
Independent reflections	8828 [R _{int} = 0.0455, R _{sigma} = 0.0532]
Completeness to theta	99 %
Absorption correction	Empirical
Data/restraints/parameters	8828 / 2 / 508
Goodness – of–fit on F ²	1.071
Final R indices [I>2 sigma(I)]	R ₁ = 0.0688, wR ₂ = 0.1647

References:

- 1 N. Sarkar, R. Kumar Sahoo and S. Nembenna, *Chem. Eur. J.*, 2023, **29**, e202203023.
- 2 A. Kaithal, B. Chatterjee and C. Gunanathan, *J. Org. Chem.*, 2016, **81**, 11153-11161.
- 3 A. Harinath, J. Bhattacharjee and T. K. Panda, *Chem. Commun.*, 2019, **55**, 1386-1389.
- 4 W. Wang, M. Luo, D. Zhu, W. Yao, L. Xu and M. Ma, *Org. Biomol. Chem.*, 2019, **17**, 3604-3608.
- 5 M. K. Barman, A. Baishya and S. Nembenna, *Dalton Trans.*, 2017, **46**, 4152-4156.
- 6 X. Cao, W. Wang, K. Lu, W. Yao, F. Xue and M. Ma, *Dalton Trans.*, 2020, **49**, 2776-2780.
- 7 M. Szewczyk, M. Magre, V. Zubar and M. Rueping, *ACS Catal.*, 2019, **9**, 11634-11639.
- 8 D. Mukherjee, A. Ellern and A. D. Sadow, *Chem. Sci.*, 2014, **5**, 959-964.
- 9 X.-X. Zhao, J. A. Kelly, A. Kostenko, S. Fujimori and S. Inoue, *Z. Anorg. Allg. Chem.*, 2022, **648**, e202200220.
- 10 G. Sheldrick, *Acta Crystallogr. C.*, 2015, **71**, 3-8.
- 11 O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, *J. Appl. Crystallogr.*, 2009, **42**, 339-341.
- 12 (a) G. M. Sheldrick, *Acta Crystallogr., Sect. A: Found. Crystallogr.*, 2008, **64**, 112-122;
(b) G. M. Sheldrick, *Acta Crystallogr., Sect. A: Found. Adv.*, 2015, **71**, 3-8.